Our model

We are focused on maximising value at all points of the investment cycle to deliver transformational treatments to patients, capture superior risk-adjusted returns for shareholders and build long-term value for all our stakeholders.

The core premise of our investment strategy is that significant risk-adjusted returns come when highly innovative technology is developed into a late-stage clinical product. Our model is to identify exceptional science and create or add companies which have the potential to develop products to late-stage development, where significant value can be accessed.